Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

June 8, 2024

https://www.globenewswire.com/news-release/2024/06/08/2895671/0/en/Akero-Therapeutics-Presents-Poster-and-Late-breaking-Oral-Presentation-on-EFX-at-the-EASL-Congress-2024.html

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations featuring its lead product candidate efruxifermin (EFX) at the European Association for the Study of the Liver (EASL) Congress 2024, in Milan, Italy. The presentations will also be available on Akero’s website following the meeting.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.